Lucid Diagnostics Inc.

LUCD Healthcare Medical Devices

Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.48 0.04 −7.69%
Market cap
$105.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
4/9
Altman Z
−10.91
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 6 4 4

+8 more TTM periods

ROE
364.89% 176.49% 152.80% 168.79%
ROA
(167.51%) (173.99%) (198.34%) (173.74%)
ROIC
(3,096.53%) (2,325.67%) (13,430.74%) (3,736.30%)
Return on Tangible Assets
(655.50%) (2,017.30%) (727.89%) (268.77%)
Average Days of Receivables
72.93 48.98 49.87 45.64
Free Cash Flow per Share
(0.26) (0.33) (0.46) (0.41)
Free Cash Flow
(47.18) (46.44) (46.68) (44.18)
Other line items

Show all line items

Columns are period end dates